Get the Stockscreener App
1.58
1.25%
-0.02
Pre-market:
1.57
-0.01
-0.63%
Cardiff Oncology Inc stock is traded at $1.58, with a volume of 403.50K.
It is down -1.25% in the last 24 hours and down -44.95% over the past month.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.
See More
Previous Close:
$1.60
Open:
$1.62
24h Volume:
403.50K
Relative Volume:
0.34
Market Cap:
$106.43M
Revenue:
$488.00K
Net Income/Loss:
$-41.44M
P/E Ratio:
-1.6989
EPS:
-0.93
Net Cash Flow:
$-31.47M
1W Performance:
+6.76%
1M Performance:
-44.95%
6M Performance:
-34.98%
1Y Performance:
-63.59%
1-Day Range:
$1.545
$1.62
1-Week Range:
$1.50
$1.64
52-Week Range:
$1.48
$4.99
Cardiff Oncology Inc Stock (CRDF) Company Profile
Name
Cardiff Oncology Inc
Sector
Industry
Phone
858-952-7570
Address
11055 FLINTKOTE AVENUE, SAN DIEGO, CA
Compare CRDF vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRDF
Cardiff Oncology Inc
|
1.58 | 107.78M | 488.00K | -41.44M | -31.47M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Cardiff Oncology Inc Stock (CRDF) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-05-26 | Initiated | Noble Capital Markets | Outperform |
| Jul-08-25 | Initiated | Ladenburg Thalmann | Buy |
| Jun-24-25 | Initiated | Jefferies | Hold |
| Sep-06-24 | Initiated | Craig Hallum | Buy |
| Jan-05-22 | Initiated | William Blair | Outperform |
| Dec-08-21 | Initiated | Robert W. Baird | Outperform |
| Aug-09-21 | Resumed | Maxim Group | Buy |
| Oct-22-20 | Initiated | H.C. Wainwright | Buy |
| Oct-08-20 | Initiated | Piper Sandler | Overweight |
View All
Cardiff Oncology Inc Stock (CRDF) Latest News
Cardiff Oncology, Inc. (NASDAQ:CRDF) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
CRDF: New CEO Presents Phase II Readout - Yahoo Finance
Leadership Turmoil Clouds Clinical Progress at Cardiff Oncology - AD HOC NEWS
Ideas Watch: Is Cardiff Oncology Inc likely to announce a buybackWeekly Gains Summary & Safe Entry Trade Reports - baoquankhu1.vn
Cardiff Oncology (CRDF) Is Down 43.9% After Advancing Onvansertib And Reshuffling Leadership Team - Yahoo Finance
Cardiff Oncology Faces Turbulence Amid Leadership Changes - StocksToTrade
CRDF: HC Wainwright & Co. Reiterates Buy Rating with $10 Price T - GuruFocus
H.C. Wainwright reiterates Buy rating on Cardiff Oncology stock at $10 - Investing.com Canada
Cardiff Oncology (CRDF) Stock Drop Presents New Investment Oppor - GuruFocus
Why Did Cardiff Oncology Stock Plunge On Tuesday?Cardiff Oncology (NASDAQ:CRDF) - Benzinga
Investors Buy High Volume of Cardiff Oncology Call Options (NASDAQ:CRDF) - Defense World
Cardiff Oncology appoints interim CEO amid leadership transition By Investing.com - Investing.com India
Cardiff To Pursue Narrower CRC Market For Onvansertib As Top Execs Step Down - Citeline News & Insights
Cardiff Oncology Overhauls Leadership to Advance Onvansertib - TipRanks
Favorite son in PLK1? Cardiff dips as phase II CRC bid advances - BioWorld MedTech
CEO transition at Cardiff Oncology (NASDAQ: CRDF) paired with positive Phase 2 trial - Stock Titan
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Cardiff Oncology (CRDF) Shares Plunge After Executive Departures and Trial Update - GuruFocus
Cardiff Oncology Shares Plunge 35% Following CEO and CFO Resignations - Intellectia AI
Cardiff Oncology Sees Unusually Large Options Volume (NASDAQ:CRDF) - MarketBeat
Cardiff Oncology Taps Interim CEO, Picks 30mg Onvansertib Regimen for 2026 Registrational mCRC Study - MarketBeat
Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development - The Globe and Mail
Cardiff Oncology down after leadership shakeup (CRDF:NASDAQ) - Seeking Alpha
Cardiff Oncology stock tumbles after Phase 2 trial data update By Investing.com - Investing.com Canada
Cardiff Oncology plunges after top executives step down - TradingView
Cardiff Oncology (CRDF) Reports Promising Phase 2 Trial Results - GuruFocus
Cardiff Oncology reports positive phase 2 data for cancer drug - Investing.com
Cardiff Oncology reports positive phase 2 data for cancer drug By Investing.com - Investing.com Nigeria
Cardiff Oncology (CRDF) Announces Leadership Changes - GuruFocus
Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC - The Manila Times
Cardiff Oncology Announces Positive Phase 2 Trial Results for Onvansertib in First-Line RAS-Mutated Metastatic Colorectal Cancer - Quiver Quantitative
Cardiff Oncology Announces Positive Update from its - GlobeNewswire
Guidance Update: Can SPAR Group Inc generate free cash flowJuly 2025 Pullbacks & Real-Time Market Sentiment Reports - baoquankhu1.vn
Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update - ADVFN
CRDFTrovagene Presents Outlook for Second Half of 2018 - ADVFN
CRDF Stock Price, Forecast & Analysis | CARDIFF ONCOLOGY INC (NASDAQ:CRDF) - Chartmill
3 Promising Penny Stocks With Market Caps Below $600M - simplywall.st
How Cardiff Oncology Inc. stock benefits from tech adoptionMorning Star Patterns & Free Long-Term Investment Planning - bollywoodhelpline.com
Gains Recap: Should you buy the dip on Cardiff Oncology Inc2025 Bull vs Bear & Weekly High Return Forecasts - baoquankhu1.vn
Will Cardiff Oncology Inc. benefit from sector rotationJuly 2025 Snapshot & Safe Entry Trade Reports - bollywoodhelpline.com
What hedge fund moves indicate for Cardiff Oncology Inc. (XE7C) stock2025 Sector Review & Weekly Setup with ROI Potential - Bollywood Helpline
Cardiff Oncology, Inc. (NASDAQ:CRDF) Receives $11.13 Consensus Price Target from Brokerages - Defense World
Cardiff Oncology: What Storms Can We Expect In 2026? The Case For Measured Enthusiasm (NASDAQ:CRDF) - Seeking Alpha
Cardiff Oncology, Inc. (NASDAQ:CRDF) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Is Cardiff Oncology Inc. stock a buy for dividend growthJuly 2025 Action & Long Hold Capital Preservation Tips - Улправда
Aug Wrap: How Cardiff Oncology Inc XE7C stock reacts to Fed tightening2025 Breakouts & Breakdowns & Fast Gain Stock Tips - Bộ Nội Vụ
How Cardiff Oncology Inc. (XE7C) stock reacts to Fed tighteningRisk Management & Stepwise Swing Trade Plans - Улправда
Equities Analysts Issue Forecasts for CRDF Q4 Earnings - Defense World
Can Cardiff Oncology Inc. stock double in next 5 yearsDividend Growth Stocks & Today’s Picks, Tomorrow’s Winners - ulpravda.ru
Q4 Earnings Estimate for CRDF Issued By Noble Financial - MarketBeat
What is Noble Financial’s Estimate for CRDF FY2025 Earnings? - Defense World
Cardiff Oncology Inc Stock (CRDF) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):